Drug Depot, LLC., dba APS Pharmacy

CLOSEOUT LETTER Drug Depot, LLC., dba APS Pharmacy MARCS-CMS 653740 — October 11, 2023 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Drugs Recipient: Recipient Name Rob Kilgore Recipient Title CEO Drug Depot, LLC., dba APS Pharmacy Belmar Pharma Solutions 12860 W. Cedar Drive, Suite 211 Lakewood , CO 80228 United States rob@belmarpharma.com Issuing Office: Division of Pharmaceutical Quality Operations II United States Dear Mr. Kilgore: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [Case #653740] issued on March 31, 2023, for Drug Depot, LLC dba APS Pharmacy, located at 34911 US Highway 19 N, Ste 600, Palm Harbor, FL 34684. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Ronda Loyd-Jones Director, Compliance Branch Office of Pharmaceutical Quality Operations, Division II cc: Via Electronic Mail Anne Szilagyi, VP of Quality Belmar Pharma Solutions 12860 W. Cedar Dr., Suite 211 Lakewood, CO 80228 Email: anne.szilagyi@belmarpharma.com Andrew M. Vukadinovich Director of Operations Drug Depot, LLC., dba APS Pharmacy 34911 US Highway 19N, Ste 600 Palm Harbor, FL 34684-1921 Email: andyv@aspsmeds.com Content current as of: 10/30/2023 Regulated Product(s) Drugs